Capital Square’s GSK GSK Stock Holding History

Capital Square’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,078	Closed	-$51K	–	197
2020 Q1	$51K	Buy	+1,078	New	+$57.5K	0.06%	205

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Capital Square's GSK Position: Q2 2020 in Review

Capital Square sold out of GSK (GSK) in Q2 2020, closing a stake of 1,078 shares — an estimated $51K sold.

Capital Square first reported a position in GSK in Q1 2020 and held it in 1 quarter. The position peaked at $51K in Q1 2020. 840 funds tracked by Wall St. Rank hold GSK as of Q2 2020.

Capital Square reported no remaining GSK position as of Q2 2020 after selling out during the quarter.
Capital Square sold 1,078 GSK shares in Q2 2020, an estimated $51K.
Capital Square first reported a position in GSK in Q1 2020 and held it in 1 quarter.
Capital Square's GSK position peaked at $51K in Q1 2020.
840 funds tracked by Wall St. Rank held GSK as of Q2 2020.

Based on Capital Square's 13F filing for Q2 2020, filed 27 Jul 2020.